A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Latest Information Update: 17 Oct 2022
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors VasGene Therapeutics
- 11 Oct 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2025.
- 11 Oct 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2024.
- 07 Oct 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2019 to 1 Jan 2021.